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Abstract
Deposition of immunoglobulin light chains is a result of clonal proliferation of monoclonal plasma cells that secrete free
immunoglobulin light chains, also called Bence Jones proteins (BJP). These BJP are present in circulation in large amounts
and excreted in urine in various light chain diseases such as light chain amyloidosis (AL), light chain deposition disease
(LCDD) and multiple myeloma (MM). BJP from patients with AL, LCDD and MM were puriﬁed from their urine and
studies were performed to determine their secondary structure, thermodynamic stability and aggregate formation kinetics.
Our results show that LCDD and MM proteins have the lowest free energy of folding while all proteins show similar melting
temperatures. Incubation of the BJP at their melting temperature produced morphologically different aggregates: amyloid
ﬁbrils from the AL proteins, amorphous aggregates from the LCDD proteins and large spherical species from the MM
proteins. The aggregates formed under in vitro conditions suggested that the various proteins derived from patients with
different light chain diseases might follow different aggregation pathways.
Introduction
Light chain amyloidosis (AL), light chain deposition
disease (LCDD) and multiple myeloma (MM) are
immunoproliferative disorders characterized by ex-
cessive proliferation of monoclonal plasma cells,
excretion of high amounts of Bence Jones proteins
(BJP) and deposition of immunoglobulin light
chains. BJP are soluble free monoclonal immuno-
globulin light chains that are secreted into circulation
and excreted in urine [1]. The symptoms and tissue
damage vary between these three light chain diseases.
AL is characterized by the deposition of immuno-
globulin light chains as amyloid ﬁbrils in vital organs
leading to organ failure. The organs most commonly
affected include the kidney, heart and liver [2]. AL
can also affect tissues such as peripheral nerve,
gastrointestinal tract and pulmonary [3]. LCDD is
characterized by granular amorphous aggregates in
the basement membrane of the kidney. The kidney is
the most frequently affected organ, but LCDD can
also occur in other organs such as the heart and
liver, where it is usually asymptomatic [4]. MM is
characterized by bone lesions, hypercalcemia, renal
failure and anemia. MM can form casts in the kidney
that can lead to renal complications [5]. Lambda
light chains are more prevalent in AL, while kappa
light chains are more prevalent in LCDD and MM
[6,7].
The ability of BJP to aggregate could be caused by
numerous factors, in particular the combination of
thermodynamic instability due to somatic mutations,
germline context and/or proteolysis [8]. According to
Hurle et al., domain stability of proteins plays an
important role in ﬁbrillogenesis. The less stable
domains tend to form aggregates and any mutation
that decreases domain stability could lead to AL [9].
There is a bias for certain germline sequences
towards amyloidogenicity. AL has a preference for
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6a, VkI O18/O8 and VkIV B3 [6]. In LCDD, there
is a preference for VkIV B3 [10]. Some possible
explanations for this bias include the fact that certain
germline gene families are more available, leading to
recombination events and clonal expansion [6]. It is
also possible that some germline genes are selected
due to their antigen diversity.
The majority of AL amyloid ﬁbrils are made up of
N-terminal fragments corresponding to the variable
domain, suggesting the possibility of a proteolytic
event. Partial proteolysis could destabilize proteins
and predispose them to form aggregates [8].
In this study, we compared the protein structure,
protein stability and aggregation properties of light
chain proteins from AL, LCDD and MM patients in
order to gain an understanding about the similarities
and differences between BJP involved in these
different light chain deposition diseases.
Methods
Cloning
Bone marrow cells were collected following the
guidelines from the Institutional Review Board at
the Mayo Clinic. RNA extracted from patients’ bone
marrow cells was used in a reverse transcriptase
polymerase chain reaction (RT-PCR) to produce
cDNA. The cDNA was ampliﬁed with degenerate
primers encoding the N-terminus of the germline
sequences by PCR (six different primers for lambda
proteins and three different primers for kappa
proteins) as previously reported [6]. Light chain
sequences were analyzed using Vbase (www.mrc-
cpe.cam.ac.uk) to determine the germline donor
sequence for each DNA variable domain sequence.
Speciﬁc germline primers corresponding to the
variable light chain gene were used to amplify the
gene corresponding to the light chain variable domain
by PCR and then cloned into pCR
1II TOPO
1 vector
following the protocol from the TOPO TA cloning
1
kit (Invitrogen, Carlsbad, CA, USA). The DNA
Synthesis and Sequencing Core Facility at the Mayo
Clinic synthesized primers and sequenced plasmids.
DNA sequences were veriﬁed in Vbase and by
BLAST 2 sequence alignment (www.ncbi.nlm.nih.
gov/blast/bl2seq/wblast2.cgi) and the sequences were
translated into their amino acid sequence using
ExPasy (www.us.expasy.org/tools/dna.html) and mu-
tations in the patient sequence were noted in com-
parison to the germline. The sequences have been
deposited in GenBank with the following acces-
sion numbers DQ240234 (AL-02), DQ240235 (AL-
03), DQ240236 (MM-01), DQ240237 (MM-02),
DQ240238 (LCDD-01), and DQ240239 (LCDD-
02, predominant VkI O12/O2 sequence).
Protein puriﬁcation
Patients’ urine samples were collected following the
guidelines from the Institutional Review Board at the
Mayo Clinic. Patients’ urine samples were dialyzed
in nanopure water overnight at 48C. The dialyzed
urine was ﬁltered with 0.22 mm disposable ﬁlter and
0.02% sodium azide was added. BJP were puriﬁed by
size exclusion chromatography using a HiLoad 16/60
Superdex 75 prep grade column on an AKTA FPLC
(GE Healthcare, Piscataway, NJ, USA) in 10 mM
Tris–HCl pH 7.4 buffer. Pure fractions were checked
by SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and stained with Coomassie blue. The
extinction coefﬁcient for each protein was calculated
using the biopolymer calculator (http://paris.chem.
yale.edu/cgi-bin/extinct.pl) which was used with its
absorbance at 280 nm to determine the protein
concentrations. Pure fractions were combined, con-
centrated and stored at 48C.
Molecular weight determination
The molecular weight of the puriﬁed protein was
determined on a Superdex 75 10/30 size exclusion
column on an AKTA FPLC (GE Healthcare) with
10 mM Tris–HCl pH 7.4 and 150 mM NaCl buffer.
Molecular weight standards of albumin, carbonic
anhydrase, cytochrome C and aprotinin (Sigma,
St Louis, MO, USA) were prepared in 10 mM
Tris–HCl pH 7.4 and 150 mM NaCl buffer with a
concentration of 3 mg/ml for aprotinin and carbonic
anhydrase and a concentration of 2 mg/ml for albu-
min and cytochrome C. The column was calibrated
with each standard at a ﬂow rate of 0.3 ml/min. The
elution volume for each standard peak was deter-
mined. The puriﬁed BJP were injected and eluted
through the column at a ﬂow rate of 0.3 ml/min.
Blue dextran, concentration of 1 mg/ml, was injected
onto the column to determine its void volume, which
is used to calculate the ratio of elution to void volume
(Ve/Vo) for each molecular weight standard. A
calibration curve was produced by plotting the
logarithms of each standard as a function of their
Ve/Vo and determining the line of best ﬁt. After
determining the Ve/Vo of each BJP, the molecular
weight was calculated by using the equation for the
line of best ﬁt.
Circular dichroism spectroscopy
Protein secondary structure was measured by Far
UV-CD spectra (260–200 nm) on an AVIV 215
circular dichroism (CD) spectrometer (AVIV Bio-
medicals Inc., Summerset, NJ, USA) in the conti-
nuous mode by taking measurements every 1 nm
with an averaging time of 5 s at 48C in a 0.2 cm
30 L. A. Sikkink & M. Ramirez-Alvaradopath-length cuvette. Protein concentrations varied
between 5.5–25.6 mM. Thermal denaturations were
carried out following the ellipticity at 218 nm
(maximum b-sheet signal) for each protein. The
ellipticity was monitored at 28C intervals from 4 to
908C with an equilibration time of 1 min and an
averaging time of 30 s in a 0.2 cm path-length
cuvette. A refolding curve was monitored immedi-
ately after the unfolding curve acquisition from 90 to
48C using the same parameters as previously stated.
Thermal denaturation data were processed following
a two-state transition model. Folded and unfolded
baselines were linear extrapolated from the data with
a minimum of 10 points for the majority of the
proteins. In some cases (uMM-02), we used fewer
points for the unfolded baseline. The fraction folded
(FF) at each temperature was calculated by using the
following equation:
FF¼(ellipticityobserved ellipticityof theunfolded)=
(ellipticityof folded ellipticityof unfolded).
Melting temperature (Tm) was calculated at the
midpoint transition for each protein. DG was
calculated according to the equation
DG(T) ¼ DHm  ð 1   T/TmÞ
  DCP½ðTm   TÞþTl nðT/TmÞ 
from Pace where DH is derived from the van’t Hoff
equation:
ln Keq ¼ð DH/RÞ ð 1=TÞþð DS/RÞ and
DCp   172 þ 17:6   N   164   SS
(in cal mol
 1 K 1Þ
where N is the number of amino acid residues and
SS is the number of disulﬁde cross-links in the
protein [11]. An alternative method tested used the
points in the FF transition to determine the free
energy of folding. The equilibrium constant (Keq)
was calculated from these points. DGfolding was
calculated using the following equation:
DGfolding ¼  RT ln Keq
where R¼gas constant (1.98 cal mol
71 K
71), T¼
temperature in Kelvin. DG(48C) was calculated by
extrapolating free energy of folding versus the
temperature to determine the line of best ﬁt for the
free energy of folding at 48C/277 K. Both methods
gave rise to very similar DGfolding values.
Chemical denaturations were done at 48C for all
proteins except for uAL-03, which was done at 228C
in a 0.2 cm path-length cuvette. A Far UV-CD
spectra of the folded (absence of urea) and unfolded
(presence of urea) samples were collected to deter-
mine the wavelength with the maximum ellipticity
difference between them. Ellipticity at that wave-
length (218 nm) was monitored in 1 s intervals
during a 60 s scan, with an equilibration time of
10 min prior to the scan. The data were averaged for
each urea concentration. Denaturation curves were
obtained by mixing equal volumes of two protein
stock solutions, in the presence and absence of urea,
to change the urea concentration while keeping the
protein concentration constant. Both the initial and
ﬁnal urea concentrations were conﬁrmed by refrac-
tometry and calculated using the equation
[urea] ¼ 117:66  ð DNÞþ29:753  ð DNÞ
2
þ 185:56  ð DNÞ
3;
where DN is the difference in refraction between the
sample and buffer [11]. The denaturation curves were
processed the same way as the two-state transition
model used in the thermal denaturation to calculate
fraction folded curves. The melting concentration of
denaturant (Cm) was determined at the midpoint
transition of the unfolding curve. DGfolding was
calculated using the same equation as used with the
thermal denaturation data. Free energy of folding
versus the concentration of urea was extrapolated to
determine the line of best ﬁt for the free energy of
folding in the absence of denaturant (DG(H2O)).
ANS binding assay
A stock solution of ANS (8-anilino-1-napthalene-
sulfonic acid) wasprepared, ﬁlteredanditsconcentra-
tion determinedbychecking its absorbance at 350 nm
and using an extinction coefﬁcient of
5000 (M cm)
71 [12]. A 5 mM protein sample was
prepared with 2.3 mM ANS in 10 mM Tris–HCl pH
7.4 buffer in the presence and absence of 6 M urea.
Samples were placed in a quartz cuvette with a path-
length of 1 cm in a temperature-controlled Model
QM-2001 ﬂuorometer (Photon Technology Interna-
tional, Lawrenceville, NJ, USA). ANS ﬂuorescence




Urine samples, pure BJP and known positive controls
were run on a SDS-PAGE gel and transferred to an
Immobilon P (PVDF) membrane (Millipore, Bill-
erica, MA, USA) using a semidry transfer apparatus
for 1 h. The membrane was blocked for 1 h in PBS
with 5% non-fat dry milk rocking at room tempera-
ture. The membrane was rocked overnight at
48C with 1:500 dilution of the primary antibody
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(AFF); The Binding Site, San Diego CA, USA) in
blocking buffer. The membrane was washed with two
washes of PBS, three washes of PBSþ0.1% Tween
20 followed by one wash with PBS. It was rocked for
1 h with a 1:8000 dilution of secondary antibody
conjugated to horseradish peroxidase (HRP; rabbit
polyclonal to sheep IgG HþL (HRP); Novus
Biologicals, Littleton, Co, USA) in blocking buffer
at room temperature. The membrane was washed
again with PBS and PBSþ0.1% Tween 20 following
the previous wash method listed above. Antibody
bound to the protein was detected using an ECL
chemiluminescence reagent (GE Healthcare) and
exposed to ﬁlm.
Aggregate formation
Aggregate formation assays incubated at the Tm of
each protein were set up with 5 mM protein in
10 mM Tris–HCl pH 7.4 buffer with 15 mM
thioﬂavine T (ThT) with a ﬁnal volume of 1.5 ml.
Samples were placed in a quartz cuvette with a stir
bar and incubated at their Tm (578C for uAL-02,
uAL-03, uMM-01 and uMM-02, 608C for uLCDD-
01 and uLCDD-02) in a temperature-controlled
Model QM-2001 ﬂuorometer (Photon Technology
International). Tryptophan ﬂuorescence was mon-
itored using an excitation wavelength of 294 nm and
emission wavelength of 350 nm. ThT ﬂuorescence
was monitored using an excitation wavelength of
450 nm and emission wavelength of 480 nm. The
two different probes were followed simultaneously
for 72 h with continuous stirring at 300 rpm.
Shutters were open only during the acquisition. All
reactions were measured in a 1 cm path-length
cuvette with slit widths of 3 nm, taking an acquisition
every 25 s with an integration time of 0.5 s.
Aggregate formation assays incubated at 378C
were set up with 5 mM protein in 10 mM Tris–HCl
pH 7.4 with 5 mM ThT in triplicate in a 384-well,
ﬂat-bottomed, high-binding, polystyrene Costar
plate (Corning Incorporated, Corning, NY, USA)
in a GENios FL plate reader (TECAN US, Durham,
NC, USA). The plate was incubated at 378C with a
reading occurring every 15 min with 3 min of
shaking prior to each reading.
Electron microscopy (EM)
Endpoint samples from the aggregation experiments
were centrifuged and resuspended in 100 ml of buffer.
Three microliters of the concentrated aggregate was
placed on a 300-mesh copper formvar/carbon grid
and negatively stained witheither4%uranylacetate or
1% phosphotungstic acid and examined on a JEOL
1200 EX transmission electron microscope.
Amino acid analysis
Ten micrograms of each protein were sent to
Scientiﬁc Research Consortium, Inc. in St. Paul,
Minnesota where acid hydrolysis was performed.
Trypsin digestion/tandem mass spectrometry and mass
spectrometry intact mass analysis
Twenty-ﬁve micrograms of each protein were taken
to the Mayo Clinic Proteomics Research Center to
carry out trypsin digestion/tandem mass spectro-
metry and intact mass analysis. The proteins to be
analyzed by nanoLC-ESI-tandem mass spectrometry
were initially reduced and alkylated with DTT and
iodoacetamide, digested with trypsin and the pep-
tides run on a ThermoFinnigan LTQ Orbitrap. The
MS/MS spectra were searched with Sequest using
both Swiss-Prot database and the expected peptides
from the sample protein sequences. Intact mass
measurements were made by LC-MS using a C18
reverse-phase HPLC column eluting into an Agilent
LC/MSD TOF mass spectrometer.
Results
We studied two BJP for each type of light chain
disease. These BJP were called uAL-02, uAL-03,
uLCDD-01, uLCDD-02, uMM-01 and uMM-02.
The ‘u’ denotes these proteins were derived from a
patient’s urine sample and the name without the ‘u’
denotes the corresponding DNA sequence name.
Table I contains information for each protein studied
such as the germline sequence, disease, organ
involvement, year of diagnosis and conﬁrmation of
diagnosis for each protein. Each protein sequence
was translated from the DNA sequence and com-
pared with its corresponding germline to note any
mutations which are highlighted in gray in Figure 1.
AL-02 has a total of 19 mutations, AL-03 has 17
mutations, LCDD-01 has 11 mutations, LCDD-02
(VkI O12/O2) has nine mutations, LCDD-02 (VkI
L1) has eight mutations, MM-01 has seven muta-
tions and MM-02 has nine mutations.
A day 100 post-stem cell transplant bone marrow
sample was used in the cloning process for LCDD-
02. We found cDNA sequences that matched two
germline sequences, VkI O12/O2 and VkI L1. The
sequence corresponding to the VkI O12/O2 germline
was the most dominant (eight of 21 sequences) and
was used as the reference sequence for this study
(Figure 1). The nucleotide sequence comparisons for
VkI L1 samples yielded all different sequences. It is
interesting tonotethereareadifferenceofsevenamino
acids between the VkI O12/O2 and L1 germline
sequences and in comparing their nucleotide se-
quences, there are 16 nucleotide changes. Germline
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cpe.cam.ac.uk). Since the bone marrow sample used
to generate the LCDD-02 sequence was taken post-
stem cell transplant, we think it was presumably
polyclonal. Unfortunately, no pretreatment bone
marrow sample was available for LCDD-02.
In Figure 1, the protein sequence for the variable
domain of LCDD-02 is identical to MM-02 including
thelocationandnumberofmutationsinbothofthem.
Both of these protein sequences correspond to the
same germline, VkI O12/O2. However, when com-
paring the nucleotide sequences for MM-02 and
LCDD-02, there are signiﬁcant differences between
them. We analyzed 12 LCDD-02 sequences and
found nucleotide changes in different positions and at
different frequencies conﬁrming the polyclonal nature
of the sample. Taking these differences into account,
the sequences are different at a nucleotide level even
though the amino acid sequences appear identical.
The constant domains for the AL and MM proteins
were not sequenced. Most of the constant domain for
MM-01 was determined by the Mayo Clinic Proteo-
mics Research Center upon complete sequencing
analysis with the kappa constant domain from the
IMGT website (http://imgt.cines.fr/). However, based
on the small region sequenced corresponding to the
constant domain as part of the light chain variable
domain (VL) sequencing, the constant domain of the
lambda proteins was determined. There are six
possible constant domains for lambda light chains.
uAL-02hasa constant domainofIGLC1 anduAL-03
has a constant domain of IGLC2. For the MM
proteins, the unique kappa constant domain was
assigned.Thesequencesforallconstantdomainswere
found on the IMGT website (http://imgt.cines.fr/).
The proteins were puriﬁed by size exclusion
chromatography with 10 mM Tris–HCl pH 7.4
buffer. A 25–26 kDa protein band is visible in all
samplesexcept thepuriﬁedLCDDproteinswhich has
a 12 kDa protein band (Figure 2). A Western blot
conﬁrmed thepuriﬁedproteins were immunoglobulin
light chain proteins (data not shown). The molecular
weight of the proteins was veriﬁed by analytical size
exclusion chromatography (data not shown) with
uAL-02 and uAL-03 being dimers, and uLCDD-01,
uLCDD-02 and uMM-01 being monomers. uMM-
02 migrated as a pentamer according to the analytical
size exclusion column results, which could be con-
tributed to the long-term storage of pure protein at
48C before injecting onto the column (248 days).
Amino acid analysis results show 98% or more
identity to the predicted sequence from translation of
Figure 1. Sequence alignment of the variable and junction domain portions of the BJP. Donor germline sequence for each Bence Jones
protein (BJP) was determined by PCR and sequence analysis. DNA sequences were translated into the amino acid sequence. Mutations
in each protein sequence when compared to the germline sequence are highlighted in gray. The junction domain is highlighted with a
box. FR, framework region; CDR, complementarity determining region; s, b-strand. The constant domains for AL and MM proteins are
not shown here. Kappa proteins (MM) have only one constant domain. The constant domain for AL-02 is IGLC1 and for AL-03 it is
IGLC2.
Table I. Protein comparison table.





uAL-02 Lambda lI-1c AL 2003 Endomyocardial biopsy Heart, liver 25
uAL-03 Lambda lIII-3r AL 2003 Renal biopsy Renal 25
uLCDD-01 Kappa kIV-B3 LCDD 2003 Renal biopsy Renal 12
uLCDD-02 Kappa kI-012/02 LCDD 2004 Renal biopsy Renal 12
uMM-01 Kappa kII-A19 MM 1986 Lytic lesions and a metastic bone survey Bone marrow 25
uMM-02 Kappa kI-012/02 MM 2003 M spike and a negative bone x-ray Bone marrow 25
AL, light chain amyloidosis; LCDD, light chain deposition disease; MM, multiple myeloma.
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fragments had an overall good coverage of all
proteins conﬁrming the sequences from the DNA
translation. The intact mass measurement of uAL-
02, uAL-03 and uMM-01 were done by reverse-
phase LC-electrospray-TOF mass spectrometry. The
other three proteins did not give reliable results. The
reduced samples of uAL-02, uAL-03 and uMM-01
had an observed mass close to the theoretical mass
calculated for each of them.
The secondary structure of the six puriﬁed BJP
was determined by Far UV-CD spectra (260–
200 nm). We observed the expected b-sheet struc-
ture with a minimum around 218 nm for each
protein (Figure 3). No notable differences were
found in any of the spectra for these samples and all
Figure 3. AL, LCDD and MM proteins have a b-sheet
conformation by Far UV-CD. All of the BJP in this study display
a b-sheet secondary structure based on the minimum ellipticity
around 218 nm. (A) AL proteins, (B) LCDD proteins and (C)
MM proteins. Experimental conditions: all Far UV-CD scans
were performed at 48C in a 0.2 cm path-length cuvette and in
10 mM Tris–HCl pH 7.4 buffer. Protein concentrations were
determined to be between 5.5–25.6 mM.
Figure 2. SDS-PAGE of urine and puriﬁed protein for each
sample shows either a 26 kDa protein band for MM and AL
proteins or a 12 kDa protein band for LCDD proteins. (A) Lanes
2–6, urine samples; lanes 7–11, puriﬁed protein samples. Lane 1,
molecular weight marker; lanes 2 and 7, uMM-01; lanes 3 and 8,
uMM-02; lanes 4 and 9, uAL-02; lanes 5 and 10, uAL-03; lanes 6
and 11, uLCDD-01. (B) uLCDD-02 gels: lanes 1 and 3,
molecular weight marker; lane 2, urine sample; lane 4, puriﬁed
protein.
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02 has a less intense mean residue ellipticity (MRE)
value around 218 nm than the rest of the proteins
and it has a shifted maximum around 206 nm. All
proteins followed a two-state unfolding transition
with similar Tm values (Figure 4 and Table II). All of
the proteins were able to refold reversibly except for
uAL-03. uLCDD-01 and uMM-01 have the lowest
values/most favorable free energy of folding from the
thermal denaturation data (DG(48C)) while both AL
proteins show the highest/less favorable values
(Table II). The DG(H2O) calculated from chemical
denaturation data follow the same trend but show
different values. uAL-03 and uMM-02 show the
highest Cm while uMM-01 and uMM-02 show the
lowest DGfolding (Table II). Urea denaturations for
uLCDD-01 and uLCDD-02 did not follow a two-
state unfolding transition.
We conducted aggregation assays by incubating
eachprotein(5 mM)with15 mMThTin10 mMTris–
HCl pH 7.4 at their Tm (578C for uAL-02, uAL-03,
uMM-01, uMM-02, 608C for uLCDD-01, uLCDD-
02) (Table II) as was previously reported [13,14]. The
kinetics of aggregate formation were followed simulta-
neously by tryptophan and thioﬂavine T (ThT)
emission wavelengths of 350 nm and 480 nm, respec-
tively. Thechangesontryptophanﬂuorescence forthe
two AL proteins studied have different early aggrega-
tion events but eventually converge into the same
process(Figure5,panelA).Thechangesintryptophan
ﬂuorescence followed the same trend for the two
LCDD proteins but LCDD-01 had higher ﬂuores-
cence intensity throughout the whole assay when
compared to LCDD-02 (Figure 5, panel B). MM
proteins had a slight variation in the beginning of the
aggregation process but the ﬂuorescence signals
eventually converge (Figure 5, panel C). The initial
changes seen in Figure 4, panel A and B (AL and
LCDDgraphs)areduetotheinitialequilibrationofthe
protein samples to their Tm. The most signiﬁcant
changes in the BJP happened within the ﬁrst 2 h of the
reaction. In conclusion, no pattern of tryptophan
ﬂuorescence can be matched to the different aggrega-
tion processes by the different BJP proteins.
The intensity of the initial and endpoint ThT
ﬂuorescence for each BJP is summarized in Figure 6
along with the fold change for each protein. The
largest fold change is found in both of the AL
proteins. The formation of ﬁbrils or aggregates was
conﬁrmed by EM as seen in Figure 7. Both of the AL
proteins formed ﬁbrils with a diameter ranging from
14–50 nm. LCDD proteins formed amorphous
aggregates with diameters between 50–300 nm.
MM proteins formed spherical species with dia-
meters of 100–150 nm. MM and LCDD proteins are
considered non-pathologic due to the lack of the
formation of ﬁbrils.
Figure 4. AL, LCDD and MM proteins have similar two state
thermal unfolding transitions. Thermal denaturations were fol-
lowed by CD following ellipticity at a wavelength of 218 nm.
Unfolding and refolding curves were followed for each BJP. (A)
AL proteins, (B) LCDD proteins and (C) MM proteins. All the
BJP in this study were all able to refold reversibly except for uAL-
03. The Tm for the proteins are 57.28C for uAL-02, 57.38C for
uAL-03, 59.68C for uLCDD-01, 56.08C for uLCDD-02, 56.68C
for uMM-01 and 57.88C for uMM-02. Protein concentrations are
between 5.5 and 25.6 mM in 10 mM Tris–HCl pH 7.4 buffer in a
0.2 cm path-length cuvette.
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cence after 8 days following the aggregation kinetics
of the samples at 378C. The fold change for the
proteins at 378C is lower than the fold change at their
Tm. This would suggest the ability to form aggregates
under these conditions is occurring slower than
samples incubated at their Tm with continuous
agitation of 300 rpm (Figure 6).
Discussion
The predicted amino acid sequences from the cloned
MM-02 and LCDD-02 samples are identical for the
variable domain. However, it is important to note a
few differences between these two samples. The
nucleotide sequences are different between these two
samples. The MM-02 protein also contains the
constant domain which is missing in the LCDD-02
protein. It is possible that the dominant clone found
for LCDD-02 is not the pathologic clone but it may
be the most abundant sequence in the polyclonal
bone marrow specimen taken post-stem cell trans-
plant. MM-02 is a clonal sequence in that almost all
of the nucleotide sequences are identical. This is not
true for the LCDD-02 nucleotide sequences.
Our results indicate that BJP derived from patients
afﬂicted with these three different light chain diseases
present very similar Tm values. Both thermal and
chemical denaturation derived DGfolding values in-
dicated that MM and LCDD proteins are more
stable than AL proteins, which is in agreement with
previous reports [12,15–17].
Due to the absence of two-state unfolding transi-
tion for LCDD proteins using urea denaturation, we
wanted to know if they were sampling unfolded states
and exposing hydrophobic patches in the absence of
denaturant at room temperature. For that purpose,
the proteins were incubated with 2.3 mM ANS (8-
anilino-1-naphthalene-sulfonic acid) in the presence
and absence of 6 M urea to see if enhanced
ﬂuorescence with ANS could be detected. ANS is a
hydrophobic dye used to detect exposed hydropho-
bic surfaces as well as partially folded intermediates
[18–20]. Fluorescence enhancement of ANS in the
presence of both proteins suggested that LCDD
proteins are sampling partially unfolded states (data
not shown). The presence of 6 M urea further
enhanced ANS ﬂuorescence, which suggested that
the proteins were able to expose more hydrophobic
surfaces and therefore might be partially unfolded in






uAL-02 57.2+0.5 76.8 3.1+0.5 73.1
uAL-03 57.3+0.4 76.6 4.4+0.5 72.2
uLCDD-01 59.6+0.4 717.4 NA* NA*
uLCDD-02 56.0+1.4 712.6 NA* NA*
uMM-01 56.6+0.4 717.1 4.0+0.8 73.6
uMM-02 57.8+0.6 715.1 6.2+0.5 74.0
*Unable to determine these values due to lack of two-state
transition. AL, light chain amyloidosis; LCDD, light chain
deposition disease; MM, multiple myeloma.
Figure 5. Aggregate formation followed by tryptophan ﬂuores-
cence. (A) AL proteins, (B) LCDD proteins and (C) MM
proteins. Experimental conditions: 10 mM Tris–HCl pH 7.4
buffer, 15 mM ThT, 5 mM protein; incubated at Tm (578C for
uAL-02, uAL-03, uMM-01 and uMM-02, 608C for uLCDD-01
and uLCDD-02); stirring at 300 rpm for 72 h with a reading
occurring every 25 s with an integration time of 0.5 s; excitation
wavelength 294 nm and emission wavelength 350 nm.
36 L. A. Sikkink & M. Ramirez-Alvaradothe absence of denaturant (data not shown). Since a
two-state unfolding transition was observed when a
thermal denaturation was performed, it is possible
that the unfolded state populated in urea is different
from the one populated at high temperatures. The
LCDD proteins in this study lack the constant
domain, which may help explain their lack of a
two-state unfolding transition when followed by
urea.
Striking differences between the different BJP were
found in their aggregation properties. The different
BJP were incubated at their Tm in 10 mM Tris–HCl
pH 7.4 buffer for 72 h. These solution conditions
have been reported to maximize aggregation
[13,14,21]. Our results show the largest fold change
in the ThT ﬂuorescence intensity between the initial
and endpoints for the AL proteins.
According to our results, the tryptophan emission
ﬂuorescence decreases in intensity over time
during the in vitro aggregation assay for all the BJP
in this study. The changes in the signal can be in
response to conformational transitions, denaturation
or changes in the environment of the protein [22].
The proteins studied were modeled using 1BRE.pdb
(k) and 1CD0.pdb (l) to determine the location of
each tryptophan residue in the protein to get an idea
of which ones were contributing to the ﬂuorescence
which may help us understand the conformational
changes occurring during aggregation. The six pro-
teins studied have a tryptophan residue at position
35. Both of the AL proteins have four tryptophan
residues which are in the same position in each of
these sequences even though they belong to two
different variable and constant domain germline
sequences. The two tryptophan residues in the
MM proteins are in the same position even though
they belong to different germline sequences. LCDD-
01 has two tryptophan residues one at position 35
protein and tryptophan 50. LCDD-02 only has one
tryptophan in the variable region at position 35.
AL proteins formed amyloid ﬁbrils with diameters
of 14–50 nm. These diameters are slightly larger
than the range of 7–12 nm that has been previously
reported for the variable domain amyloid ﬁbrils [23].
The difference in diameter could be due to the
presence of the constant domain as part of the ﬁbril.
MM proteins consistently formed large spherical
species with diameters of 100–150 nm, which is
contrary to previous reports of variable domain MM
proteins that were able to form amyloid ﬁbrils
[16,24–26]. LCDD proteins formed predominantly
amorphous aggregates that had diameters of 50–
300 nm. MM and LCDD proteins did not form
ﬁbrils and in turn are non-pathogenic.
What causes a protein to misfold and form either
ﬁbrils or aggregates? Clues to the type of aggregation
formed by a protein could be found in the pathway
the protein follows in becoming an aggregate. The
aggregation pathway could be either an on- or off-
folding pathway, going through a possible inter-
mediate before reaching its form of deposition.
Khurana et al. has reported that partially unfolded
intermediates could lead to ﬁbrils or amorphous
aggregates [12]. According to Vidal et al., off-
pathway aggregation does not necessarily form
amyloid ﬁbrils. For example, in LCDD, the forma-
tion of ﬁbrils may be avoided due to the formation of
intermediates that lead to aggregate formation in an
off-pathway fashion [27]. Figure 8 shows a model of
the various misfolding pathways a protein could
follow on its way to becoming an aggregate. It is
possible the spheres formed by MM proteins and
LCDD amorphous aggregates are a trapped inter-
mediate state (most likely off-pathway) after 72 h of
incubation and are unable to proceed to ﬁbrils. It is
not known if over time the protein will be able to
leave this trapped state and go on to form ﬁbrils.
The mutations for the various BJP in this study can
be located throughout the protein, but they tend to
cluster in certain areas of the variable domain [28].
Figure 6. Aggregate formation followed by thioﬂavine T ﬂuores-
cence (ThT). (A) Initial and end-point ThT ﬂuorescence readings
at their Tm. (B) Fold change between initial and endpoint ThT
ﬂuorescence readings from samples incubated at either their Tm or
at 378C. Experimental conditions: 10 mM Tris–HCl pH 7.4
buffer, 15 mM ThT, 5 mM protein; incubated at Tm (578C for
uAL-02, uAL-03, uMM-01 and uMM-02, 608C for uLCDD-01
and uLCDD-02) with stirring at 300 rpm for 72 h with a reading
occurring every 25 s with an integration time of 0.5 s.
Analysis of Bence Jones proteins from different light chain diseases 37The variable domain has an immunoglobulin fold
consisting of two antiparallel b-sheets packed to-
gether and joined by a disulﬁde bond [29]. AL
proteins have the largest number of mutations out of
the six proteins studied and most of their mutations
are located in the b-sheet that is part of the heavy
chain/light chain dimer interface. uLCDD-01 has
mutations in the top or bottom of the beta barrel.
uMM-01, uMM-02, and uLCDD-02 have their
mutations located in the N and C terminus strands.
Figure 8. Model for protein folding and misfolding where aggregation may occur through an on or off pathway intermediate.
Figure 7. AL proteins show amyloid ﬁbrils. LCDD proteins show amorphous aggregates and MM proteins show spherical species. uAL-03
and uLCDD-02 were stained with 4% uranyl acetate. uAL-02, uLCDD-01, uMM-01 and uMM-02 were stained with 1% phosphotungstic
acid. The negatively stained grids were examined using a JEOL 1200 EX transmission electron microscope. Scale bars are located in the
lower left corner of each image.
38 L. A. Sikkink & M. Ramirez-AlvaradoIn conclusion, we have determined thermody-
namic parameters for human derived BJP, we have
characterized the aggregation properties and de-
scribed their differences. This study has shed some
light into the differences among BJP involved in
different light chain diseases.
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